Belimumab, a B-cell-targeted biologic that neutralizes soluble B lymphocyte stimulator (BLyS), is the first FDA-approved therapy for systemic lupus erythematosus (SLE). This evidence concerns the gene TNFSF13B and systemic lupus erythematosus.